<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/24/analysts-set-spring-bank-pharmaceuticals-inc-nasdaqsbph-target-price-at-20-00.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-24T19:46:41+00:00"/>
    <meta property="og:title" content="Analysts Set Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) Target Price at $20.00"/>
    <meta property="og:description" content="Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) has been given an average recommendation of “Buy” by the seven brokerages that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price target among brokers that have […]"/>
  </head>
  <body>
    <article>
      <h1>Analysts Set Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) Target Price at $20.00</h1>
      <address><time datetime="2019-11-24T19:46:41+00:00">24 Nov 2019, 19:46</time> by <a rel="author" href="https://www.thecerbatgem.com/author/amy" target="_blank">Amy Steele</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/spring-bank-pharmaceuticals-inc-logo.png"/>
      </figure>
      <p>Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) has been given an average recommendation of “Buy” by the seven brokerages that are covering the company, <a href="https://www.marketbeat.com/">MarketBeat Ratings</a> reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $20.00.</p>
      <p>A number of equities research analysts have recently commented on SBPH shares. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> cut shares of Spring Bank Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, October 5th. B. Riley reduced their target price on shares of Spring Bank Pharmaceuticals from $24.00 to $16.00 and set a “buy” rating for the company in a report on Monday, August 5th. Finally, <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=SBPH">ValuEngine</a> raised shares of Spring Bank Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.</p>
      <p>Several institutional investors have recently modified their holdings of SBPH. Arcadia Investment Management Corp MI acquired a new position in shares of Spring Bank Pharmaceuticals during the second quarter worth about $44,000. JPMorgan Chase &amp; Co. increased its stake in shares of Spring Bank Pharmaceuticals by 35.5% during the second quarter. JPMorgan Chase &amp; Co. now owns 25,064 shares of the company’s stock worth $98,000 after acquiring an additional 6,565 shares during the period. Hikari Power Ltd increased its stake in shares of Spring Bank Pharmaceuticals by 14.6% during the second quarter. Hikari Power Ltd now owns 61,336 shares of the company’s stock worth $226,000 after acquiring an additional 7,800 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Spring Bank Pharmaceuticals during the second quarter worth about $29,000. Finally, Renaissance Technologies LLC increased its stake in shares of Spring Bank Pharmaceuticals by 255.6% during the second quarter. Renaissance Technologies LLC now owns 131,200 shares of the company’s stock worth $484,000 after acquiring an additional 94,300 shares during the period. Institutional investors and hedge funds own 42.05% of the company’s stock.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NASDAQ/SBPH/price-target/">SBPH stock</a> traded down $0.02 on Friday, reaching $3.01. 27,200 shares of the stock were exchanged, compared to its average volume of 40,573. The business’s 50 day moving average price is $3.11 and its 200 day moving average price is $4.30. Spring Bank Pharmaceuticals has a twelve month low of $2.75 and a twelve month high of $12.31. The company has a current ratio of 12.18, a quick ratio of 12.18 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $49.92 million, a price-to-earnings ratio of -1.61 and a beta of 0.47.</p>
      <p>Spring Bank Pharmaceuticals (NASDAQ:SBPH) last announced its earnings results on Thursday, November 7th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.19. Equities research analysts forecast that Spring Bank Pharmaceuticals will post -2.29 earnings per share for the current year.</p>
      <p>
        <b>About Spring Bank Pharmaceuticals</b>
      </p>
      <p>Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).</p>
      <p>Further Reading: <a href="https://www.marketbeat.com/financial-terms/growth-stocks-what-they-are/">Investing in Growth Stocks</a></p>
      <figure>
        <img src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SBPH"/>
      </figure>
    </article>
  </body>
</html>